Literature DB >> 22648903

Compartmental tissue distribution of antibody therapeutics: experimental approaches and interpretations.

C Andrew Boswell1, Daniela Bumbaca, Paul J Fielder, Leslie A Khawli.   

Abstract

Monoclonal antibodies have provided many validated and potential new therapeutic candidates for various diseases encompassing the realms of neurology, ophthalmology, immunology, and especially oncology. The mechanism of action for these biological molecules typically involves specific binding to a soluble ligand or cell surface protein in order to block or alter a molecular pathway, induce a desired cellular response, or deplete a target cell. Many antigens reside within the interstitial space, the fluid-filled compartment that lies between the outer endothelial vessel wall and the plasma membranes of cells. This mini-review examines the concepts relevant to the kinetics and behavior of antibodies within the interstitium with a special emphasis on radiometric measurement of quantitative pharmacology. Molecular probes are discussed to outline chemical techniques, selection criteria, data interpretation, and relevance to the study of antibody pharmacokinetics. The importance of studying the tissue uptake of antibodies at a compartmental level is highlighted, including a brief overview of receptor occupancy and its interpretation in radiotracer studies. Experimental methods for measuring the spatial composition of tissues are examined in terms of relative vascular, interstitial, and cellular volumes using solid tumors as a representative example. Experimental methods and physiologically based pharmacokinetic modeling are introduced as distinct approaches to distinguish between free and bound fractions of interstitial antibody. Overall, the review outlines the available methods for pharmacokinetic measurements of antibodies and physiological measurements of the compartments that they occupy, while emphasizing that such approaches may not fully capture the complexities of dynamic, heterogeneous tumors and other tissues.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22648903      PMCID: PMC3385837          DOI: 10.1208/s12248-012-9374-1

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  40 in total

1.  Maximizing tumour exposure to anti-neuropilin-1 antibody requires saturation of non-tumour tissue antigenic sinks in mice.

Authors:  Daniela Bumbaca; Hong Xiang; C Andrew Boswell; Ruediger E Port; Shannon L Stainton; Eduardo E Mundo; Sheila Ulufatu; Anil Bagri; Frank-Peter Theil; Paul J Fielder; Leslie A Khawli; Ben-Quan Shen
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

Review 2.  Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis.

Authors:  Meindert Danhof; Joost de Jongh; Elizabeth C M De Lange; Oscar Della Pasqua; Bart A Ploeger; Rob A Voskuyl
Journal:  Annu Rev Pharmacol Toxicol       Date:  2007       Impact factor: 13.820

3.  IL-12: monoclonal antibodies specific for the 40-kDa subunit block receptor binding and biologic activity on activated human lymphoblasts.

Authors:  R Chizzonite; T Truitt; F J Podlaski; A G Wolitzky; P M Quinn; P Nunes; A S Stern; M K Gately
Journal:  J Immunol       Date:  1991-09-01       Impact factor: 5.422

Review 4.  Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view.

Authors:  C Andrew Boswell; Martin W Brechbiel
Journal:  Nucl Med Biol       Date:  2007-06-08       Impact factor: 2.408

5.  Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model.

Authors:  Cinthia V Pastuskovas; Eduardo E Mundo; Simon P Williams; Tapan K Nayak; Jason Ho; Sheila Ulufatu; Suzanna Clark; Sarajane Ross; Eric Cheng; Kathryn Parsons-Reponte; Gary Cain; Marjie Van Hoy; Nicholas Majidy; Sheila Bheddah; Josefa dela Cruz Chuh; Katherine R Kozak; Nicholas Lewin-Koh; Peter Nauka; Daniela Bumbaca; Mark Sliwkowski; Jay Tibbitts; Frank-Peter Theil; Paul J Fielder; Leslie A Khawli; C Andrew Boswell
Journal:  Mol Cancer Ther       Date:  2012-01-05       Impact factor: 6.261

6.  The processing and fate of antibodies and their radiolabels bound to the surface of tumor cells in vitro: a comparison of nine radiolabels.

Authors:  L B Shih; S R Thorpe; G L Griffiths; H Diril; G L Ong; H J Hansen; D M Goldenberg; M J Mattes
Journal:  J Nucl Med       Date:  1994-05       Impact factor: 10.057

7.  Quantitative autoradiographic evaluation of the influence of protein dose on monoclonal antibody distribution in human ovarian adenocarcinoma xenografts.

Authors:  F E Yang; R S Brown; K F Koral; A C Clavo; G A Jackson; R L Wahl
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

Review 8.  Elimination mechanisms of therapeutic monoclonal antibodies.

Authors:  Mohammad A Tabrizi; Chih-Ming L Tseng; Lorin K Roskos
Journal:  Drug Discov Today       Date:  2006-01       Impact factor: 7.851

9.  Theoretic criteria for antibody penetration into solid tumors and micrometastases.

Authors:  Greg M Thurber; Stefan C Zajic; K Dane Wittrup
Journal:  J Nucl Med       Date:  2007-05-15       Impact factor: 10.057

10.  Identification of metabolites of 111In-diethylenetriaminepentaacetic acid-monoclonal antibodies and antibody fragments in vivo.

Authors:  B E Rogers; F N Franano; J R Duncan; W B Edwards; C J Anderson; J M Connett; M J Welch
Journal:  Cancer Res       Date:  1995-12-01       Impact factor: 12.701

View more
  23 in total

1.  Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor.

Authors:  Rong Deng; Daniela Bumbaca; Cinthia V Pastuskovas; C Andrew Boswell; David West; Kyra J Cowan; Henry Chiu; Jacqueline McBride; Clarissa Johnson; Yan Xin; Hartmut Koeppen; Maya Leabman; Suhasini Iyer
Journal:  MAbs       Date:  2016-02-26       Impact factor: 5.857

2.  Balancing charge in the complementarity-determining regions of humanized mAbs without affecting pI reduces non-specific binding and improves the pharmacokinetics.

Authors:  Amita Datta-Mannan; Arunkumar Thangaraju; Donmienne Leung; Ying Tang; Derrick R Witcher; Jirong Lu; Victor J Wroblewski
Journal:  MAbs       Date:  2015       Impact factor: 5.857

3.  Interstitial IgG antibody pharmacokinetics assessed by combined in vivo- and physiologically-based pharmacokinetic modelling approaches.

Authors:  Miro J Eigenmann; Tine V Karlsen; Ben-Fillippo Krippendorff; Olav Tenstad; Ludivine Fronton; Michael B Otteneder; Helge Wiig
Journal:  J Physiol       Date:  2017-10-29       Impact factor: 5.182

4.  Deciphering the In Vivo Performance of a Monoclonal Antibody to Neutralize Its Soluble Target at the Site of Action in a Mouse Collagen-Induced Arthritis Model.

Authors:  Weirong Wang; Thomas S McIntosh; Xiling Jiang; Rajitha Doddareddy; Elayne C Dell; Honghui Zhou
Journal:  Pharm Res       Date:  2015-12-30       Impact factor: 4.200

Review 5.  Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer.

Authors:  Paul Malik; Colin Phipps; Andrea Edginton; Jonathan Blay
Journal:  Pharm Res       Date:  2017-09-18       Impact factor: 4.200

6.  An integrated approach to identify normal tissue expression of targets for antibody-drug conjugates: case study of TENB2.

Authors:  C Andrew Boswell; Eduardo E Mundo; Ron Firestein; Crystal Zhang; Weiguang Mao; Herman Gill; Cynthia Young; Nina Ljumanovic; Shannon Stainton; Sheila Ulufatu; Aimee Fourie; Katherine R Kozak; Reina Fuji; Paul Polakis; Leslie A Khawli; Kedan Lin
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

7.  Tissue Physiology of Cynomolgus Monkeys: Cross-Species Comparison and Implications for Translational Pharmacology.

Authors:  Danielle Mandikian; Isabel Figueroa; Amy Oldendorp; Hanine Rafidi; Sheila Ulufatu; Michelle G Schweiger; Jessica A Couch; Noel Dybdal; Sean B Joseph; Saileta Prabhu; Gregory Z Ferl; C Andrew Boswell
Journal:  AAPS J       Date:  2018-10-08       Impact factor: 4.009

8.  Whole-Body Pharmacokinetics of Antibody in Mice Determined using Enzyme-Linked Immunosorbent Assay and Derivation of Tissue Interstitial Concentrations.

Authors:  Hsuan-Ping Chang; Se Jin Kim; Dhaval K Shah
Journal:  J Pharm Sci       Date:  2020-06-02       Impact factor: 3.534

9.  GIPR antagonist antibodies conjugated to GLP-1 peptide are bispecific molecules that decrease weight in obese mice and monkeys.

Authors:  Shu-Chen Lu; Michelle Chen; Larissa Atangan; Elizabeth A Killion; Renee Komorowski; Yuan Cheng; Chawita Netirojjanakul; James R Falsey; Marina Stolina; Denise Dwyer; Clarence Hale; Shanaka Stanislaus; Todd Hager; Veena A Thomas; John M Harrold; David J Lloyd; Murielle M Véniant
Journal:  Cell Rep Med       Date:  2021-04-30

10.  Transferrin receptor (TfR) trafficking determines brain uptake of TfR antibody affinity variants.

Authors:  Nga Bien-Ly; Y Joy Yu; Daniela Bumbaca; Justin Elstrott; C Andrew Boswell; Yin Zhang; Wilman Luk; Yanmei Lu; Mark S Dennis; Robby M Weimer; Inhee Chung; Ryan J Watts
Journal:  J Exp Med       Date:  2014-01-27       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.